Anzeige
Mehr »
Montag, 21.09.2026 - Börsentäglich über 12.000 News
114 Proben. 114 mit Gallium.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
313 Leser
Artikel bewerten:
(1)

Indegene Inc: Tealium and Indegene partner to help life sciences brands with robust customer data strategies to deliver superior customer experiences

PRINCETON, N.J. and BENGALURU, India, Sept. 29, 2022, announced a strategic collaboration to combine Tealium's customer data platform (CDP) solutions with Indegene's life sciences domain knowledge and advanced data and analytics expertise. The partnership enables life sciences organizations to drive faster and better business decisions, elevate healthcare professionals' (HCPs) and patients' journeys, and enhance brand engagement.

As life sciences organizations prioritize HCP engagement and customer experience, capturing every moment of HCP interaction becomes vital to elevating their overall experience. However, with the large amount of HCP and patient data across millions of interactions, life sciences organizations often struggle to connect and collate this data in a central and secure place, and then use it for their communication strategies. As a result, these organizations are missing out on valuable patient insights that fuel business decisions in real-time.

Indegene will help global life sciences organizations of all sizes modernize their customer data priorities with Tealium. The joint capabilities are built to resolve customer data collection and storage, marketing automation and implementation, and data and analytics - ensuring life sciences brands can leverage the full power of customer data intelligence based on HCP, patient, and caregiver data. This seamlessly drives personalized and real-time messaging to target audiences and improves customer engagement across regions and brands. Also, with real-time dashboard and reporting integrations, the joint proposition boosts customer insights at a granular level and elevates the overall customer experience (CX) vision.

"As a leading global digital-first, life sciences commercialization partner, we are excited to collaborate with Tealium and help life sciences brands with embedded and AI-driven data capabilities that boost their omnichannel CX priorities. With the latest Tealium for Pharmaoffering, we enable global life sciences commercial teams with powerful data and identity management capabilities, allowing them to craft personalized and relevant experiences with life sciences brands," says Vivek Ghai, SVP, Indegene Enterprise Commercial. "We will also help global life sciences brands uncover their customer behavioral insights and patterns from data silos across channels around the world - a key area that helps them become not just data first, but future ready."

"Indegene's life sciences domain knowledge and advanced data and analytics expertise are key to providing personalized real-time messaging to target audiences. Together, we will help our life sciences clients leverage the Tealium for Pharmaplatform to collect, enrich and activate relevant data for the HCP, patient and caregiver. A more engaging, privacy-centric approach leveraging best-of-breed services from both Tealium and Indegene will have accelerated outcomes," says Matthew Gray, VP, Global Partnerships at Tealium.

Jay Calavas, Head of Vertical Products at Tealium, continued, "The life sciences industry is extremely dynamic and deals with many complexities unique to its space, including regulations and navigating a constantly evolving ecosystem. That's why having a robust customer data strategy is critical. To take our platform to the next level, Tealium is proud to activate integrations with Indegene to zero in on life science companies' ability to create better journeys for its customers, ultimately leading to better patient experiences."

About Indegene
Indegene is a technology-led healthcare solutions provider. It combines deep industry expertise with fit-for-purpose technology in an agile and scalable operating model. Many of the leading, global healthcare organizations rely on Indegene to deliver effective and efficient clinical, medical and commercial outcomes every day. From strategy to execution, Indegene enables healthcare organizations be future ready. To learn more about how Indegene delivers on its purpose, please visit www.indegene.com

About Tealium

Tealium connects customer data across the web, mobile, offline, and IoT so businesses can better connect with their customers. Tealium's turnkey integration ecosystem supports more than 1,300 built-in connections, empowering brands to create a complete, real-time customer data infrastructure. Tealium's solutions include a customer data platform with machine learning, tag management, an API hub and data management solutions that make customer data more valuable, actionable, privacy-compliant and secure. More than 850 leading businesses throughout the world trust Tealium to power their customer data strategies. For more information, visit www.tealium.com.

For media inquiries, please contact:
Yadunandan K V
yadunandan.kv@indegene.com


© 2022 GlobeNewswire (Europe)
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.